
Experimental women's cancer drug boosts survival rates in notable study
Fox News
Researchers discuss encouraging findings on a new drug tested in a phase 3 trial, which showed significant improvement in patients with treatment-resistant ovarian cancer.
The ROSELLA trial, conducted in collaboration with The GOG Foundation, analyzed 381 patients around the world, including the U.S., Europe, South Korea, Brazil, Argentina, Canada and Australia, according to a press release. "A 30% decrease in risk of recurrence and a 31% decreased risk of death is promising." Angelica Stabile is a lifestyle reporter for Fox News Digital.
The large, randomized phase 3 study revealed a 30% reduction in risk of disease progression in patients with platinum-resistant ovarian cancer, compared to those just treated with nab-paclitaxel. (Some types of chemotherapy contain the element platinum.)